2013-08-22 12:37:50 - RNCOS has recently added a new Market Research Report titled, “Cancer Monoclonal Antibodies Market Forecast to 2017” to its report gallery. This report provides extensive research on the Cancer Monoclonal Antibodies Market.
Cancer, one of the leading causes of death worldwide, affected approximately 13 Million people in 2012 and this figure is expected to grow to 17 Million by 2020. The dramatic increase in the size of the potential cancer market has prompted pharmaceutical players to invest in the oncology sector with major focus on monoclonal antibodies.
Monoclonal antibodies identify cancer cells, bind to proteins on their surface, and stimulate an immune response so are very specific to targets. Various monoclonal antibodies for treatment of cancer are available in the market and many more are in the pipeline. According to RNCOS' report, “Cancer Monoclonal Antibodies Market Forecast to 2017”, the market for cancer mAbs is estimated at US$ 24 Billion, and is expected
to grow to around US$ 34 Billion by 2017.
The report, in particular, provides an insight to the global burden of cancer, with detailed breakdown of incidences by type and geography. It not only estimates the current burden but also makes future predictions. There is an exhaustive overview of the monoclonal technology, helping the client understand the various types of antibodies and the diverse types of cancer therapies which make use of mAbs.
In our report, we have profiled every anti-cancer monoclonal antibody available in the market and estimated the current and future market of five of them. The report covers major trends which are driving the current market and a country level analysis of the status of cancer mAbs.
Through our pipeline analysis of the various mAbs, it has been revealed that majority of the mAbs in the pipeline are in phase III trials with most of them devoted to Solid Tumor, Lung Cancer, Breast Cancer, and NHL. The approval of these drugs will drive a major change in the market in terms of market share of current drugs.
Finally, RNCOS concludes its report with a competitive analysis of the major mAb players, providing brief descriptions of every player along with a list of current and pipeline mAbs. The report can therefore, provide assistance in evaluating the current market, discovering potential areas and analyzing the competitive environment.
For FREE SAMPLE of this report visit: www.rncos.com/Report/IM620.htm
Some of our Related Reports are:
- Cancer Monoclonal Antibodies Market to 2015 ( www.rncos.com/Report/IM375.htm
- Global Gene Therapy Market Analysis ( www.rncos.com/Report/IM282.htm
- Erythropoietin Market Forecast to 2015 ( www.rncos.com/Report/IM428.htm
Check Related REPORTS on: www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.